Please use this identifier to cite or link to this item:
|Title:||Editorial. Nomenclature - Avoiding Babylonian Speech Confusion in Present Day Immunology|
|Author:||van Zelm, Menno C.|
Ziegler Heitbrock, Loems
Collins, Andrew M.
Chan, Sanny K.
Engel Rocamora, Pablo
|Abstract:||The complexity of the immune system at the gene, protein, cell, and organism levels continues to provide a major challenge. Genomic landscaping, single-cell analysis and mass data acquisition including genome, transcriptome, metabolome, and proteome have now added new levels of complexity. With the rapid progress in these and other fields of immunology, it has become more important than ever to agree on uniform nomenclatures, i.e. to agree on how to name novel genes, proteins, cells, and biological reagents. Names given initially might, in retrospect, not always be logical. For example, tumor necrosis factor (TNF) was named on the basis of the observation of central necrosis in an experimental subcutaneous mouse tumor model (1). It was only after many unsuccessful studies in cancer, that eventually the role of TNF as a master cytokine in inflammation emerged. By that time, it was too late to rename the molecule because that would cause renewed confusion. Another cytokine has been successfully renamed. Interleukin-6 was initially known as B-cell Stimulatory Factor 2, Cytotoxic T lymphocyte Differentiation Factor, Hybridoma Growth Factor, Hepatocyte Stimulating Factor, and Interferon Beta-2. Obviously, such usage of different names for the same item can lead to confusion and may hinder progress in the field. These two examples demonstrate the need for a consensus nomenclature, which is timely applied.|
|Note:||Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2020.621100|
|It is part of:||Frontiers in Immunology, 2020, vol. 11, num. 621100|
|Appears in Collections:||Articles publicats en revistes (Biomedicina)|
This item is licensed under a Creative Commons License